These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 11777396)

  • 1. Allosterically controllable maxizyme-mediated suppression of progression of leukemia in mice.
    Kuwabara T; Tanabe T; Warashina M; Xiong KX; Tani K; Taira K; Asano S
    Biomacromolecules; 2001; 2(4):1220-8. PubMed ID: 11777396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosterically controlled single-chained maxizymes with extremely high and specific activity.
    Kuwabara T; Hamada M; Warashina M; Taira K
    Biomacromolecules; 2001; 2(3):788-99. PubMed ID: 11710033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel allosterically trans-activated ribozyme, the maxizyme, with exceptional specificity in vitro and in vivo.
    Kuwabara T; Warashina M; Tanabe T; Tani K; Asano S; Taira K
    Mol Cell; 1998 Nov; 2(5):617-27. PubMed ID: 9844634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Target therapy for CML--applying maxizyme].
    Tani K
    Nihon Rinsho; 2001 Dec; 59(12):2439-44. PubMed ID: 11766353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogene inactivation in a mouse model.
    Tanabe T; Kuwabara T; Warashina M; Tani K; Taira K; Asano S
    Nature; 2000 Aug; 406(6795):473-4. PubMed ID: 10952298
    [No Abstract]   [Full Text] [Related]  

  • 6. A novel maxizyme vector targeting a bcr-abl fusion gene induced specific cell death in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Soda Y; Tani K; Bai Y; Saiki M; Chen M; Izawa K; Kobayashi S; Takahashi S; Uchimaru K; Kuwabara T; Warashina M; Tanabe T; Miyoshi H; Sugita K; Nakazawa S; Tojo A; Taira K; Asano S
    Blood; 2004 Jul; 104(2):356-63. PubMed ID: 15039277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specificity of novel allosterically trans- and cis-activated connected maxizymes that are designed to suppress BCR-ABL expression.
    Hamada M; Kuwabara T; Warashina M; Nakayama A; Taira K
    FEBS Lett; 1999 Nov; 461(1-2):77-85. PubMed ID: 10561500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
    Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
    Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
    Wu Y; Chen YZ; Huang HF; Chen P; Lu LH
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Working at the cutting edge: the creation of allosteric ribozymes.
    Warashina M; Kuwabara T; Taira K
    Structure; 2000 Nov; 8(11):R207-12. PubMed ID: 11080644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia.
    Lin H; Monaco G; Sun T; Ling X; Stephens C; Xie S; Belmont J; Arlinghaus R
    Oncogene; 2005 May; 24(20):3246-56. PubMed ID: 15735695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model.
    Park J; Kim KI; Koh Y; Won NH; Oh JM; Lee DS; Kim BK; Ahn KS; Yoon SS
    Exp Hematol; 2010 Sep; 38(9):773-81. PubMed ID: 20438801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
    Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
    J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-alpha and bcr-abl antisense oligodeoxynucleotides in combination enhance the antileukemic effect and the adherence of CML progenitors to preformed stroma.
    Bellucci R; Sala R; De Propris MS; Cordone I; de Fabritiis P
    Leuk Lymphoma; 1999 Nov; 35(5-6):471-81. PubMed ID: 10609784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.
    Skorski T; Nieborowska-Skorska M; Nicolaides NC; Szczylik C; Iversen P; Iozzo RV; Zon G; Calabretta B
    Proc Natl Acad Sci U S A; 1994 May; 91(10):4504-8. PubMed ID: 8183938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multilineage outgrowth of both malignant and normal hemopoietic progenitor cells from individual chronic myeloid leukemia patients in immunodeficient mice.
    Verstegen MM; Cornelissen JJ; Terpstra W; Wagemaker G; Wognum AW
    Leukemia; 1999 Apr; 13(4):618-28. PubMed ID: 10214871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
    Kuroda J; Kimura S; Andreeff M; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Murotani Y; Matsumoto Y; Tanaka H; Strasser A; Taniwaki M; Maekawa T
    Br J Haematol; 2008 Jan; 140(2):181-90. PubMed ID: 18028486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosterically controllable maxizymes for molecular gene therapy.
    Iyo M; Kawasaki H; Taira K
    Curr Opin Mol Ther; 2002 Apr; 4(2):154-65. PubMed ID: 12044037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
    Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.